[cancerpage is a service of Alere]
 


[home]
[search the site]
[my cancerpage]
[ribbon project]
[stories and experiences]
[glossary of terms]
[journal of hope]
[comments]
[about us]
[policies and disclaimers]
[physician and service directories]

Sectioning Spots Malignancy After Salpingo-Oophorectomy

NEW YORK JAN 27, 2005 (Reuters Health) - Use of a rigorous operative and pathological protocol in BRCA mutation carriers who undergo bilateral risk-reducing salpingo-oophorectomy (RRSO) increases the rate of occult ovarian malignancy detection, according to the results of a small study reported in the January 1st issue of the Journal of Clinical Oncology.

Dr. John L. Ziegler of the University of California San Francisco Comprehensive Cancer Center, and colleagues note that women with deleterious mutation of BRCA1 or BRCA2 genes are at increased risk of ovarian cancer and after childbearing may elect to undergo RRSO.

Recent studies have reported occult malignancy in 2.5% of such women. To increase the detection rate, the researchers adopted a protocol that included complete removal and serial sectioning of both ovaries and fallopian tubes, as well as biopsies and cytological examination of peritoneal washings.

In 41 women who underwent RRSO, the protocol was followed completely or partially and revealed seven occult malignancies (17%), of which six were microscopic. All were found due to protocol-associated procedures, not standard procedures.

Moreover, other factors such as age, parity, mutation type and surgery "did not alter the strong effect of the protocol on cancer detection," the researchers report.

Should these results be confirmed, they conclude, "additional staging, chemotherapy, and follow-up may be necessary in affected women."

SOURCE:

  • Journal of Clinical Oncology 2005;23:127-132.



"Reuters content is the intellectual property of Reuters Limited. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon."
 

 MedlinePlus is a resource for health information offered to the public by the US Government. The search box below will direct you to publicly available health information from the National Institutes of Health, the FDA and other government agencies.
Search MEDLINEplus:
 

MEDLINEplus en español

 
We subscribe to the HONcode principles of the Health On the Net Foundation


cancerpage.com 2000
- 2009 . Please send your feedback, comments and suggestions to our staff. Read our policies and terms of service . cancerpage.com is a service of Alere® .
© (2009) Inverness Medical. All Rights Reserved. Alere is a trademark of the Inverness Medical group of companies.